

SMV

Combining the high energies of Sopha and Summit

Sopha Medical and Summit Nuclear have merged to form a dynamic new company. As *SMV*, our combined forces are focused on being the finest nuclear medicine imaging company in the world.

Behind our new name stands a history rich in nuclear medicine *firsts*. In 1985 it was the first 32 bit computer. In 1991 the first variable angle camera. Not to mention advanced all-digital detectors and the most envied clinical software in the business. All of which resulted in new industry standards for quality, efficiency and value.

As *SMV*, our combination of powerful resources and strong financing, underscored by \$50 million in committed capital, enables us to continue building on this tradition of excellence. To better meet the needs of our customers, *SMV* offers the most diverse


product line-up in nuclear medicine. We offer solutions for meeting the vast array of clinical and economic requirements, and support them with comprehensive customer service.

Now, as you might expect from the world's largest dedicated nuclear medicine company, the *SMV* commitment to research and development spans the globe. Our mission — discover new practical solutions which expand the clinical value and use of nuclear medicine. Assuring Sopha, Summit and *SMV* customers — currently numbering over 3,500 systems in 50 countries — a steady stream of enhancements to keep their investment right up with the cutting-edge for years to come.

If you are considering a new nuclear medicine imaging system, plug into the high energy of *SMV*. For more information on our dynamic new company, products and services,

please contact:





<i>SMV International</i>	
<i>SMV America, Inc.</i>	41, rue Fourny
1993 Case Parkway	ZI BP 112
Twinsburg, Ohio 44087	78534 Buc France
1-800-664-0844	(33-1) 30-84-91-00



The Next Generation

TRIAD XLT 20 Whole BodySPECT

Superior Clinical Imaging



Best Image Resolution

- PROXIMA Real-time Auto Body-Contouring
- Center-of-Rotation and Axial Alignment accuracy guaranteed to 0.1mm rms
- Angular accuracy guaranteed to 0.1° rms
- Patented linearity and X-Y shift correction

New Imaging Applications in Nuclear Medicine

- Whole BodySPECT multiple FOV SPECT
- 511 keV F-18 FDG SPECT
- Gated Cardiac SPECT/ Ejection Fraction

Imaging Complete Patient Population

- Industry-best 20 in. axial FOV
- Industry-best 30 in. patient imaging aperture
- 500 lb. patient weight capacity
- 6 ft. 4 in. patient height imaging capacity

Best Clinical Throughput

- Entire torso SPECT in one rotation
- Entire torso three planar views
- Six-view WholeBody Scan in 22 minutes
- Whole BodySPECT up to 6 ft. 4 in.
- Optimized for Oncology Applications

Patient Comfort

- 36 in. Open Access Gantry
- Elegant "Whisper-Quiet" Operation
- Extra-wide Patient Table



Efficient Clinical Operation

- QuickVIEW Swing Arm P-scope
- Automated Pre-Scan System Setup
- Simple Protocol-based Scan Setup
- State-of-the-art Sun computing speed

TRIONIX XLT Products Workstation

Sun SPARCstation 20, Model 71

- SuperSPARC II CPU
 - 204.7 MIPS
 - 125.8 SPECint92
 - 121.2 SPECfp92
- 36 KByte Internal Cache Memory
- 1 MByte External Cache Memory
- 128 MByte Main Memory
- Two-1.05 GByte Internal Disk Drives



Odyssey™ VP

HIGH TECHNOLOGY LEADERSHIP ?

Judge For Yourself



TRIONIX
RESEARCH LABORATORY, INC.

8037 Bavaria Road • Twinsburg, Ohio 44087 USA • Telephone: (216) 425-9055 • Fax: (216) 425-9059

e-mail: sales@trionix.com

© 1995, TRIONIX Research Laboratory, Inc.

All trademarks are the property of their respective companies.

T006014, Rev. A

May, 1995



**IF THIS IS YOUR GAMMA
CAMERA WOULD YOU BE
SATISFIED WITH
THESE COLLIMATORS!**



You have a good Gamma Camera system, with a powerful computer system and advanced software. Of course these are essential to your day to day operations. However it does not guarantee that you will get artifact free images.

Your choice of collimators should be an integral part of choosing your Camera system and computer. **MICRO-CAST COLLIMATORS** from **NUCLEAR FIELDS** will guarantee artifact free images. Independent tests at clinical sites have proven that the inferior quality of foil constructed collimators produce disturbing artifacts.

Why compromise your expensive investment by accepting inferior foil constructed collimators. A few simple tests can determine the quality of your collimators. Demand from your camera supplier **MICRO-CAST** collimators, if they are really concerned about your image quality they would not enforce foil constructed collimators on you.

***Call your NUCLEAR FIELDS
representative for more
information.***

NUCLEAR FIELDS



NUCLEAR FIELDS B.V.
Akkervoorweg 3-11
5827 AP Vortum-Mullem
P.O. Box 136
5830 AC Boxmeer
THE NETHERLANDS
Phone: 08855-73544
Fax: 08855-75391

**NUCLEAR FIELDS
(U.S.A.) CORP.**
1645 S. River RD., #5
Des Plaines, Illinois 60018
U.S.A.
Phone: (708) 299-8450
1-800-932-7203
Fax: (708) 299-8452


**NUCLEAR FIELDS
PTY. LTD. (AUST.)**
No. 17 Plasser Crescent
St. Marys, NSW 2760
AUSTRALIA
Phone: (02) 673-4033
Fax: (02) 673-4264

Available from CAPINTEC the ULTIMATE Building Blocks for All HOT LABS

When putting in a new Hot Lab, choose the Capintec Hot Lab Package for the ULTIMATE in value and convenience.

Capintec offers two complete packages containing everything that you will need to get started.


Save time and money by taking advantage of these Hot Lab Packages plus our years of experience in Nuclear Medicine.



CRC®-15R Dose Calibrator

The group of products shown is only a sample of the total packages offered. For a complete list of top quality products contained in these packages give us a call at 1-800-ASK-4-CRC.


Should you require a specialized package for Cardiology, Oncology, or Radiopharmacy, Capintec will supply the appropriate products to meet your needs.



UNILOCK™ Syringe Shields



Tungsten Vial Shields




Reference Sources



Flood Sources



Shielded Syringe Carriers



Nuclear Medicine Phantoms



Portable Survey Meters



Table Top "L" Bench Shields



Lead Lined Sharps Containers

CAPINTEC. ONE STOP SHOPPING. IT JUST MAKES SENSE!



CAPINTEC, INC.

6 Arrow Rd. • Ramsey, NJ 07446
1-800-ASK-4-CRC • Fax: 201-825-4829
Circle Reader Service No. 23

THE SOURCE FOR RADIOISOTOPE SHIELDING AND STORAGE

Biodex Medical Systems offers a wide range of Radioisotope shielding and handling products all designed specifically to meet the demanding needs of the Nuclear Medicine professional.

A Full array of Syringe Shields including the Pro-Tec® II the NEW Pro-Tec III and the NEW 'All-View' Glass Syringe Shield

• ALL-VIEW SYRINGE SHIELD

This new syringe shield features 360° viewing through 6.2 density leaded glass with tip-to-tip visibility.

• **PRO-TEC III** The all new Syringe Shield featuring a unique Safe-T-Lock design that immediately grips and secures the syringe in place and releases it by the simple press of a button.

• **PRO-TEC II** Our most popular syringe shield. Designed for the clinician who has previously found it difficult to work with conventional syringe shields. Lightweight, tensile strength of steel, and tungsten shielding make the pencil thin Pro-Tec II a popular choice.

Other syringe shields include:

- DOSE DRAWING SYRINGE SHIELD
- PRO-TEC β SYRINGE SHIELD
- THALLIUM INJECTION SHIELD
- COLOR CODED LEAD GLASS AND LEAD ACRYLIC SYRINGE SHIELDS
- COLOR CODED AND STANDARD VIAL SHIELDS
- TUNGSTEN AND LEAD GLASS VIAL SHIELDS and more...

The Biodex Line of quality LEAD LINED Shielding and Storage Products is unmatched for quality and design. A full assortment of modular furniture, affording the technologist the right module for the job. Whether custom designed or standard Biodex can meet your most demanding specifications.

• **RADIOISOTOPE STORAGE MODULES** Specified with either 1/2" or 1" lead shielding on all 6 sides, and 8-12 key locked, lead lined drawers this module is a must in all hot labs.

• **PREPARATION ENCLOSURE** This counter mounted fume hood connects to external ductwork and is completely shielded with 1/4" lead encased in stainless steel.

• **LEAD LINED WASTE CONTAINER** a must for any facility that generates radioactive waste. Constructed entirely of stainless steel, the container features a step action flip-top and 1/8" lead shielding.

• **TABLE TOP LEAD BARRIER SHIELDS** these shields come in two sizes mini and standard- choose the size that fits your workload.


A complete line of Sharps Shields, Syringe Holders, Storage Containers and Protective Clothing including:

• **LEAD LINED SHARPS SHIELDS** safely contains "HOT", used syringes prior to final disposal. Choose either a single or the NEW Dual Container model.

• **LEAD SHIELDED SYRINGE HOLDERS** either single or multiple styles to choose from.




PRO-TEC III
Syringe Shield



ALL-VIEW
SYRINGE SHIELD



Table Top
BARRIER SHIELD



Lead lined
SHARPS SHIELD



Radioisotope
MODULAR FURNITURE


BIODEX
MEDICAL

CALL 1-800-224-6339 FOR A

THE ATOMLABTM FAMILY OF NUCLEAR PRODUCTS



ATOMLABTM
Dose Calibrators



ATOMLABTM 950
Thyroid Uptake System



ATOMLABTM 450
Wipe Test System

THE ATOMLABTM 100 DOSE CALIBRATOR

- All functions are microprocessor controlled
- Ultra-fast response
- Automatic range selection
- Automatic background subtraction and zeroing
- Remote ionization chamber with 10-foot cable
- Self-diagnostic software
- Daily constancy isotope keys
- Electronic power supply (no battery in chamber)
- Industry exclusive 2-year warranty
- UL listed

The AtomlabTM 100 uses specially designed software and microprocessor technology to provide fast, accurate activity measurements with performance that easily surpasses the latest most, stringent regulatory requirements.

THE ATOMLABTM 100^{plus} DOSE CALIBRATOR

- All the feature of the AtomlabTM 100 as well as:
 - Clock/Calendar
 - Prints "peel & stick" syringe / report labels
 - 3 daily constancy isotope keys
 - Prints constancy reports with carbonless copies for Co-57, Cs-137, and Ba-133
 - Saves up to 2 months of constancy data.
 - Sr-89 now pre-defined
 - RS-232 serial port standard
- The new Atomlab 100^{plus} performs all standard dose calibration and then some. With more features than the Atomlab 100 at less cost than the Atomlab 200 - Atomlab 100^{plus} is a great investment.

THE ATOMLABTM 200 DOSE CALIBRATOR

- Inventory control of 25 samples, correcting for volume, activity and moly concentration
- Volume determination and future dose computations
- Pharmaceutical purity quality control
- Isotope decay protection
- Automatic linearity calculations using attenuator tubes
- All enhanced functions performed with push button control
- Advanced dot matrix printer

THE ATOMLABTM 300 DOSE CALIBRATOR

- Extended measurement range
- Ultra-fast response time
- Factory calibrated for all PET isotopes

The Atomlab 300 PET Dose Calibrator is designed specifically to meet the needs of Positron Emission Tomography. It's ultra-fast response time, extended measurement range and computer compatibility provide state of the art performance for both clinical as well as research PET.

THE ATOMLABTM 450 WIPE TEST SYSTEM

- Complete wipe test system including Schilling, red cell survival, blood volume.
- Macintosh based
- Easy to use
- 1024 Channel MCA
- Isotope discrimination, identification and spectral analysis.

THE ATOMLABTM 950 THYROID UPTAKE SYSTEM

- The only POWER MAC based Thyroid Uptake System
 - Easy to learn, easy to use
 - 1024 Channel Multi-Channel Analyzer
 - Real-time patient data
 - In-Vitro programs for RBC Survival and Blood Volume
 - NEW Hematology Mode includes programs for GFR and ERPF
 - Extensive Wipe Test program
 - Compatible with any Macintosh software program
- The new Atomlab 950 Uptake System combines the speed, sophistication and ease of use of a Power Mac with the creative programming of Biodex to produce the first Mac-based Thyroid Uptake System. Just turn it on and go.

THE ATOMLABTM 930 THYROID UPTAKE SYSTEM

- Fast, accurate reproducible results
 - Auto-calculation and calibration
 - Complements any size nuclear medicine department
 - Uptakes, Bioassay, Wipe Testing, Schilling, Manual MCA mode and more....
- The Atomlab 930 is a complete Thyroid Uptake System specifically designed for nuclear medicine professionals, capable of performing a wide array of functions including Updates, Bioassay, Wipe Test, Schilling, Manual MCA mode.

BIODEX
MEDICAL

FREE 150 PAGE BIODEX CATALOG

Bracco: Experts in the nature of imaging.

Bracco: Recognized worldwide for expertise in contrast media.

Bracco Diagnostics Inc. is the U.S. subsidiary of Bracco S.p.A., which has a 60-year history of internationally recognized leadership in contrast media. Our worldwide team of research scientists has an outstanding record in the development of contrast agents for diagnostic imaging.

Bracco: Bringing you the complete line of Squibb®* Diagnostics products.

As you know, Bracco acquired the complete Squibb Diagnostics product line of x-ray and MRI contrast media as well as nuclear medicine products in August 1994. All products formerly from Squibb Diagnostics will now be available only from Bracco Diagnostics and will carry Bracco labels.


Bracco: Committed to your present needs and to the future of diagnostic imaging.

You can rely on Bracco Diagnostics Inc. to provide excellent service and support to complement our outstanding products. And because we have the largest team of imaging research scientists in the world, you can also expect significant new products carrying the Bracco name.

For more information call 1-800-631-5245.

This image of a radiographed hibiscus symbolizes the delicacy of the human body undergoing examination—illustrating the importance of using contrast agents that respect the body's natural harmony. "Harmony in Contrast" reflects the Bracco commitment to offering products that achieve this goal.





Harmony in Contrast



How to recognize a candidate for Cardiolite®

The shape of your patients may help you recognize the potential for soft-tissue attenuation, especially in fleshy figures.

For female and large-chested or obese male patients, Cardiolite comes through with higher photon energy (140 keV) to provide images with greater anatomical detail. Clear images can enhance interpretive confidence—which may reduce false-positives and equivocal cases.

Cardiolite also offers the unique advantage of direct measurement of both myocardial perfusion and ventricular function from one study.

So the next time you're faced with imaging female and large-chested or obese male patients, use Cardiolite and reduce soft-tissue attenuation.

Cardiolite

Kit for the preparation of Technetium Tc99m Sestamibi

To reduce soft-tissue attenuation Cardiolite comes through



Stress testing should be performed only under the supervision of a qualified physician in a laboratory equipped with appropriate resuscitation and support apparatus. There have been infrequent reports of signs and symptoms consistent with seizure and severe hypersensitivity after administration of Tc99m Sestamibi.

Please see brief summary of prescribing information on adjacent page.

© 1994, DuPont Pharma

Safety and effectiveness in children below the age of 18 have not been established.

Cardiolite®

Kit for the preparation of Technetium Tc99m Sestamibi

FOR DIAGNOSTIC USE

DESCRIPTION: Each 5ml vial contains a sterile, non-pyrogenic, lyophilized mixture of:
Tetrakis (2-methoxy isobutyl isonitrile) Copper (I) tetrafluoroborate - 1.0mg
Sodium Citrate Dihydrate - 2.6mg
L-Cysteine Hydrochloride Monohydrate - 1.0mg
Mannitol - 20mg
Stannous Chloride, Dihydrate, minimum (SnCl₂•2H₂O) - 0.025mg
Stannous Chloride, Dihydrate, (SnCl₂•2H₂O) - 0.075mg
Tin Chloride (Stannous and Stannic) Dihydrate, maximum (as SnCl₂•2H₂O) - 0.086mg

Prior to lyophilization the pH is 5.3-5.9. The contents of the vial are lyophilized and stored under nitrogen.

This drug is administered by intravenous injection for diagnostic use after reconstitution with sterile, non-pyrogenic, oxidant-free Sodium Pertechnetate Tc99m Injection. The pH of the reconstituted product is 5.5 (5.0-6.0). No bacteriostatic preservative is present.

The precise structure of the technetium complex is Tc99m[MIBI]₆⁺ where MIBI is 2-methoxy isobutyl isonitrile.

INDICATIONS AND USAGE: CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is a myocardial perfusion agent that is useful in the evaluation of ischemic heart disease. CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is useful in distinguishing normal from abnormal myocardium and in the localization of the abnormality, in patients with suspected myocardial infarction, ischemic heart disease or coronary artery disease. Evaluation of ischemic heart disease or coronary artery disease is accomplished using rest and stress techniques.

CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is also useful in the evaluation of myocardial function using the first pass technique.

Rest-exercise imaging with Tc99m Sestamibi in conjunction with other diagnostic information may be used to evaluate ischemic heart disease and its localization.

In clinical trials, using a template consisting of the anterior wall, inferior-posterior wall and isolated apex, localization in the anterior or inferior-posterior wall in patients with suspected angina pectoris or coronary artery disease was shown. Disease localization isolated to the apex has not been established. Tc99m Sestamibi has not been studied or evaluated in other cardiac diseases.

It is usually not possible to differentiate recent from old myocardial infarction or to differentiate recent myocardial infarction from ischemia.

CONTRAINDICATIONS: None known.

WARNINGS: In studying patients in whom cardiac disease is known or suspected, care should be taken to assure continuous monitoring and treatment in accordance with safe, accepted clinical procedure. Infrequently, death has occurred 4 to 24 hours after Tc99m Sestamibi use and is usually associated with exercise stress testing (See Precautions).

PRECAUTIONS:

GENERAL

The contents of the vial are intended only for use in the preparation of Technetium Tc99m Sestamibi and are not to be administered directly to the patient without first undergoing the preparative procedure.

Radioactive drugs must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to the patients consistent with proper patient management.

Contents of the kit before preparation are not radioactive. However, after the Sodium Pertechnetate Tc99m Injection is added, adequate shielding of the final preparation must be maintained.

The components of the kit are sterile and non-pyrogenic. It is essential to follow directions carefully and to adhere to strict aseptic procedures during preparation.

Technetium Tc99m labeling reactions involved depend on maintaining the stannous ion in the reduced state. Hence, Sodium Pertechnetate Tc99m Injection containing oxidants should not be used.

Technetium Tc99m Sestamibi should not be used more than six hours after preparation.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

Stress testing should be performed only under the supervision of a qualified physician and in a laboratory equipped with appropriate resuscitation and support apparatus.

The most frequent exercise stress test endpoints, which resulted in termination of the test during controlled Tc99m Sestamibi studies (two-thirds were cardiac patients) were:

Fatigue	35%
Dyspnea	17%
Chest Pain	16%
ST-depression	7%
Arrhythmia	1%

Carcinogenesis, Mutagenesis, Impairment of Fertility

In comparison with most other diagnostic technetium labeled radiopharmaceuticals, the radiation dose to the ovaries (1.5rads/30mCi at rest, 1.2 rads/30mCi at exercise) is high. Minimal exposure (ALARA) is necessary in women of childbearing capability. (See Dosimetry subsection in DOSAGE AND ADMINISTRATION section.)

The active intermediate, [Cu(MIBI)₆]⁺, was evaluated for genotoxic potential in a battery of five tests. No genotoxic activity was observed in the Ames, CHO/HPRT and sister chromatid exchange tests (all *in vitro*). At cytotoxic concentrations (≥ 20μg/ml), an increase in cells with chromosome aberrations was observed in the *in vitro* human lymphocyte assay. [Cu(MIBI)₆]⁺ did not show genotoxic effects in the *in vivo* mouse micronucleus test at a dose which caused systemic and bone marrow toxicity (9mg/kg, > 600 × maximal human dose).

Pregnancy Category C

Animal reproduction and teratogenicity studies have not been conducted with Technetium Tc99m Sestamibi. It is also not known whether Technetium Tc99m Sestamibi can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. There have been no studies in pregnant women. Technetium Tc99m Sestamibi should be given to a pregnant woman only if clearly needed.

Nursing Mothers

Technetium Tc99m Pertechnetate is excreted in human milk during lactation. It is not known whether Technetium Tc99m Sestamibi is excreted in human milk. Therefore, formula feedings should be substituted for breast feedings.

ADVERSE REACTIONS: During clinical trials, approximately 8% of patients experienced a transient parosmia and/or taste perversion (metallic or bitter taste) immediately after the injection of Technetium Tc99m Sestamibi. A few cases of transient headache, flushing, edema, injection site inflammation, dyspepsia, nausea, vomiting, pruritus, rash, urticaria, dry mouth, fever, dizziness, fatigue, dyspnea, and hypotension also have been attributed to administration of the agent. Cases of angina, chest pain, and death have occurred (see Warnings and Precautions). The following adverse reactions have been rarely reported: signs and symptoms consistent with seizure occurring shortly after administration of the agent; transient arthritis in a wrist joint; and severe hypersensitivity, which was characterized by dyspnea, hypotension, bradycardia, asthenia and vomiting within two hours after a second injection of Technetium Tc99m Sestamibi.

DOSAGE AND ADMINISTRATION: The suggested dose range for I.V. administration in a single dose to be employed in the average patient (70kg) is:

370-1110MBq (10-30mCi)

The dose administered should be the lowest required to provide an adequate study consistent with ALARA principles (see also PRECAUTIONS).

When used in the diagnosis of myocardial infarction, imaging should be completed within four hours after administration.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. Radiochemical purity should be checked prior to patient administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Store at 15-25°C before and after reconstitution.

RADIATION DOSIMETRY: The radiation doses to organs and tissues of an average patient (70kg) per 1110MBq (30mCi) of Technetium Tc99m Sestamibi injected intravenously are shown in Table 4.

Table 4. Radiation Absorbed Doses from Tc99m Sestamibi

Organ	Estimated Radiation Absorbed Dose			
	REST			
	2.0 hour void		4.8 hour void	
	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.9
Gallbladder Wall	2.0	20.0	2.0	20.0
Small Intestine	3.0	30.0	3.0	30.0
Upper Large Intestine Wall	5.4	55.5	5.4	55.5
Lower Large Intestine Wall	3.9	40.0	4.2	41.1
Stomach Wall	0.6	6.1	0.6	5.8
Heart Wall	0.5	5.1	0.5	4.9
Kidneys	2.0	20.0	2.0	20.0
Liver	0.6	5.8	0.6	5.7
Lungs	0.3	2.8	0.3	2.7
Bone Surfaces	0.7	6.8	0.7	6.4
Thyroid	0.7	7.0	0.7	6.8
Ovaries	1.5	15.5	1.6	15.5
Testes	0.3	3.4	0.4	3.9
Red Marrow	0.5	5.1	0.5	5.0
Urinary Bladder Wall	2.0	20.0	4.2	41.1
Total Body	0.5	4.8	0.5	4.8

Organ	STRESS			
	2.0 hour void		4.8 hour void	
	rads/ 30mCi	mGy/ 1110MBq	rads/ 30mCi	mGy/ 1110MBq
Breasts	0.2	2.0	0.2	1.8
Gallbladder Wall	2.8	28.9	2.8	27.8
Small Intestine	2.4	24.4	2.4	24.4
Upper Large Intestine Wall	4.5	44.4	4.5	44.4
Lower Large Intestine Wall	3.3	32.2	3.3	32.2
Stomach Wall	0.5	5.3	0.5	5.2
Heart Wall	0.5	5.6	0.5	5.3
Kidneys	1.7	16.7	1.7	16.7
Liver	0.4	4.2	0.4	4.1
Lungs	0.3	2.6	0.2	2.4
Bone Surfaces	0.6	6.2	0.6	6.0
Thyroid	0.3	2.7	0.2	2.4
Ovaries	1.2	12.2	1.3	13.3
Testes	0.3	3.1	0.3	3.4
Red Marrow	0.5	4.6	0.5	4.4
Urinary Bladder Wall	1.5	15.5	3.0	30.0
Total Body	0.4	4.2	0.4	4.2

Radiopharmaceutical Internal Dose Information Center, July, 1990, Oak Ridge Associated Universities, P.O. Box 117, Oak Ridge, TN 37831, (615) 576-3449.

HOW SUPPLIED: Du Pont Radiopharmaceuticals' CARDIOLITE®, Kit for the Preparation of Technetium Tc99m Sestamibi is supplied as a 5ml vial in kits of two (2), five (5) and thirty (30) vials, sterile and non-pyrogenic.

Prior to lyophilization the pH is between 5.3-5.9. The contents of the vials are lyophilized and stored under nitrogen. Store at 15-25°C before and after reconstitution. Technetium Tc99m Sestamibi contains no preservatives. Included in each two (2) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each five (5) vial kit are one (1) package insert, six (6) vial shield labels and six (6) radiation warning labels. Included in each thirty (30) vial kit are one (1) package insert, thirty (30) vial shield labels and thirty (30) radiation warning labels.

The U.S. Nuclear Regulatory Commission has approved this reagent kit for distribution to persons licensed to use byproduct material pursuant to section 35.11 and section 35.200 of Title 10 CFR Part 35, to persons who hold an equivalent license issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.



Radiopharmaceuticals

Marketed by
Du Pont Radiopharmaceutical Division
The Du Pont Merck Pharmaceutical Co.
331 Treble Cove Road
Billerica, Massachusetts, USA 01862

New from DuPont Radiopharmaceuticals:
High Quality and Extended Stability
in a SPECT Brain Perfusion Agent

**JUST WHAT YOU'RE
LOOKING FOR...**




Introducing a **NEW** SPECT Brain Perfusion Agent

NEUROLITE[®]

KIT FOR THE PREPARATION OF TECHNETIUM Tc99m BICISATE INJECTION

Technetium Tc99m Bicisate should be used with caution in patients with renal or hepatic impairment since it is eliminated primarily by renal excretion. Adverse reactions are rare ($\leq 1\%$). For details, see Adverse Reactions section of the prescribing information. In clinical trials, at least one of three readers of Neurolite[®] images (blinded to all other clinical information) correctly diagnosed stroke for 85% of the subjects with stroke while unblinded interpretation of CT/MRI images resulted in the correct diagnosis of stroke in 88% of subjects with stroke. There were 11 false positive and 34 false negative interpretations of Neurolite images and 0 false positive and 31 false negative interpretations of CT/MRI results.




Normal images, using Neurolite, of a 36-year-old female.

—Courtesy of Thomas C. Hill, MD,
Deaconess Hospital, Boston, Mass

NEW

Just what you're looking for...
HIGH-QUALITY IMAGES...
EXTENDED STABILITY...



High-Definition Perfusion Images

Well-defined lesions

- ◆ Clear definition of perfusion defects as determined by visual analysis

High brain-to-background activity

- ◆ Clear delineation between brain and background structures early after injection

Extended In Vitro Stability

The SPECT brain agent with 6-hour stability after preparation

- ◆ Allows for more flexible patient scheduling
- ◆ Useful in the acute setting since doses can be prepared beforehand
- ◆ Enables SPECT brain imaging to be used with agitated or uncooperative patients where study delays are often encountered
- ◆ Allows for convenience of unit dosing

Please see brief summary of prescribing information at the end of this advertisement.

Introducing Neurolite®



JUST WHAT YOU'RE LOOKING FOR...

Desirable pharmacokinetics/dosimetry

- ◆ Accumulates rapidly in the brain^{1,2}
- ◆ Localizes as a function of regional brain perfusion, cellular uptake, and metabolism within the cells
- ◆ Rapid blood clearance—(< 10% remains in the blood after 1 minute, < 5% after 60 minutes)
- ◆ A dosing range of 10-30 mCi of Neurolite provides the flexibility to achieve improved image quality and/or reduced imaging time¹

Simple room-temperature preparation

One-step quality control procedure

NEUROLITE®

KIT FOR THE PREPARATION OF TECHNETIUM Tc99m BICISATE INJECTION

Quality you expect. Stability you need.

Please see brief summary of
prescribing information on adjacent page.

DU PONT
PHARMA

Radiopharmaceuticals

Neurolite® is a registered trademark of the DuPont Merck Pharmaceutical Company.

© 1995, Du Pont Pharma

2/95

♻️ Printed on Recycled Paper

NEUROLITE®

KIT FOR THE PREPARATION OF TECHNETIUM Tc99m BICISATE INJECTION

FOR DIAGNOSTIC USE

The following is a brief summary. For more information please see complete prescribing information.

INDICATIONS

Neurolite single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed.

Neurolite is not indicated for assessment of functional viability of brain tissue. Also, Neurolite is not indicated for distinguishing between stroke and other brain lesions.

CONTRAINDICATIONS

None known.

WARNINGS

None known.

PRECAUTIONS

General

USE WITH CAUTION IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT. TECHNETIUM Tc99m BICISATE IS ELIMINATED PRIMARILY BY RENAL EXCRETION. WHETHER TECHNETIUM Tc99m BICISATE IS DIALYZABLE IS NOT KNOWN. DOSE ADJUSTMENTS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT HAVE NOT BEEN STUDIED.

Patients should be encouraged to drink fluids and to void frequently during the 2-6 hours immediately after injection to minimize radiation dose to the bladder and other target organs.

Contents of the vials are intended only for use in the preparation of Technetium Tc99m Bicisate and are not to be administered directly to the patient without first undergoing the preparation procedure.

The contents of each vial are sterile and nonpyrogenic. To maintain sterility, aseptic technique must be used during all operations in the manipulation and administration of Neurolite.

Technetium Tc99m Bicisate should be used within six hours of the time of preparation.

As with any other radioactive material, appropriate shielding should be used to avoid unnecessary radiation exposure to the patient, occupational workers, and other people.

Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies have not been conducted to evaluate carcinogenic potential or effects on fertility. When tested in vitro, Neurolite prepared with decayed generator eluate induced unscheduled DNA synthesis in rat hepatocytes and caused an increased frequency of sister chromatid exchanges in CHO cells; but, it did not induce chromosome aberrations in human lymphocytes or cause gene mutations in the Ames test or in a CHO/HGPRT test. Unreacted bicisate dihydrochloride increased the apparent rate of gene mutation of the TA 97a strain of *S. typhimurium* in the Ames test; but, it did not demonstrate clastogenic activity in an in vivo micronucleus assay in mice.

Pregnancy: Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with Technetium Tc99m Bicisate. It is also not known whether Technetium Tc99m Bicisate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, Technetium Tc99m Bicisate should not be administered to a pregnant woman unless the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Technetium Tc99m Pertechnetate can be excreted in human milk. Therefore, formula should be substituted for breast milk until the technetium has cleared from the body of the nursing woman.

Pediatric Use

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

In clinical trials, Neurolite has been administered to 1022 subjects (262 normals, 760 patients). Of these, 548 (54%) were men and 473 (46%) were women. The mean age was 58 years (range 17 to 92 years). In the 760 patients who had experienced neurologic events, there were 11 (1.4%) deaths, none of which were clearly attributed to Neurolite.

A total of 60 subjects experienced adverse reactions; the adverse reaction rates were comparable in the <65 year and the >65 year age groups.

The following adverse effects were observed in ≤1% of the subjects: headache, dizziness, seizure, agitation/anxiety, malaise/somnolence, parosmia, hallucinations, rash, nausea, syncope, cardiac failure, hypertension, angina, and apnea/cyanosis.

In clinical trials of 197 patients, there were inconsistent changes in the serum calcium and phosphate levels. The cause of the changes has not been identified and their frequency and magnitude have not been clearly characterized. None of the changes required medical intervention.

DOSAGE AND ADMINISTRATION

Before administration, a patient should be well hydrated. After administration, the patient should be encouraged to drink fluids liberally and to void frequently.

The recommended dose range for intravenous administration for a 70 kg patient is 370 - 1110 MBq (10-30 mCi). Dose adjustments for age, weight, gender, or renal or hepatic impairment have not been studied.

The dose for the patient should be measured by a suitable radioactivity calibration system

immediately before administration to the patient. Radiochemical purity should be checked before administration to the patient.

Neurolite, like other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Preparations containing particulate matter or discoloration should not be administered. They should be disposed of in a safe manner, in compliance with all applicable regulations.

Prior to reconstitution, vial A and vial B are stored at 15°-25°C. Protect vial A from light.

Store at room temperature (15°-30°C) after preparation.

Aseptic techniques and effective shielding should be employed in withdrawing doses for administration to patients. Waterproof gloves and effective shielding should be worn when handling the product.

RADIATION DOSIMETRY

The radiation doses to organs and tissues of an average patient (70 kg) for Technetium Tc99m Bicisate injected intravenously for 370 MBq (10 mCi) are shown in Table 4 and for 1110 MBq (30 mCi) are shown in Table 5.

Table 4.—Radiation Absorbed Doses From 370 MBq (10 mCi) of Technetium Tc99m Bicisate

Organ	Estimated Absorbed Radiation Dose ²			
	2.0 Hr. Void mGy/ 370 MBq	rad/s/ 10 mCi	4.8 Hr. Void mGy/ 370 MBq	rad/s/ 10 mCi
Bone Surfaces	1.26	0.13	1.41	0.14
Brain	2.04	0.20	2.04	0.20
Gallbladder Wall	9.25	0.91	9.25	0.92
Intestine Wall (Lower Large)	4.81	0.47	5.55	0.55
Intestine (Small)	3.48	0.35	3.70	0.38
Intestine Wall (Upper Large)	5.92	0.61	6.29	0.63
Kidneys	2.70	0.27	2.74	0.27
Liver	1.96	0.20	2.00	0.20
Lungs	0.74	0.08	0.74	0.08
Ovaries	2.00	0.22	2.96	0.30
Red Marrow	0.89	0.09	1.00	0.10
Testes	0.81	0.08	1.33	0.13
Thyroid	1.30	0.13	1.30	0.13
Urinary Bladder Wall	11.10	1.10	27.01	2.70
Total Body	0.89	0.09	1.07	0.11

Table 5.—Radiation Absorbed Doses From 1110 MBq (30 mCi) of Technetium Tc99m Bicisate

Organ	Estimated Absorbed Radiation Dose ²			
	2.0 Hr. Void mGy/ 1110 MBq	rad/s/ 30 mCi	4.8 Hr. Void mGy/ 1110 MBq	rad/s/ 30 mCi
Bone Surfaces	3.77	0.39	4.22	0.42
Brain	6.11	0.61	6.11	0.61
Gallbladder Wall	27.75	2.73	27.75	2.76
Intestine Wall (Lower Large)	14.43	1.41	16.65	1.65
Intestine (Small)	10.43	1.05	11.10	1.14
Intestine Wall (Upper Large)	17.76	1.83	18.87	1.89
Kidneys	8.10	0.81	8.21	0.81
Liver	5.88	0.60	5.99	0.60
Lungs	2.22	0.23	2.22	0.23
Ovaries	5.99	0.66	8.88	0.90
Red Marrow	2.66	0.26	3.00	0.29
Testes	2.44	0.24	4.00	0.39
Thyroid	3.89	0.39	3.89	0.39
Urinary Bladder Wall	33.33	3.33	81.03	8.10
Total Body	2.66	0.27	3.22	0.33

²Dosimetry calculated using the MIRD software program at Oak Ridge Associated Universities, P.O. Box 117, Oakridge, TN, 29 July 1988.

**DU PONT
PHARMA**

Marketed By

DuPont Radiopharmaceutical Division
The DuPont Merck Pharmaceutical Company
331 Treble Cove Road
BillERICA, Massachusetts 01862

For Ordering Tel. Toll Free: 800-225-1572
All other business: 800-362-2668
(For Massachusetts and International, call 508-667-9531)

References: 1. Holman BL, Hellman RS, Goldsmith SJ, et al. Biodistribution, dosimetry, and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. *J Nucl Med.* 1989;30:1018-1024.
2. Vallabhajosula S, Zimmerman RE, Picard M, et al. Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. *J Nucl Med.* 1989;30:599-604.

IN A FOG??

using aerosols to determine the patency of the pulmonary airway system? Use a gas (that's what the airway system is for), and Xenon (127 or 133) are gases which are safe, economical and easy to administer with the XENAMATIC™ 3000.


- Shielded for Xe 127 and Xe 133 (radiation profile available on request).
 - World's only system that allows you to study patients on Ventilators.
 - Largest and most efficient Xenon trap with a built-in monitor alarm system.
 - Built-in O₂ monitor with digital display and control.
 - A rebreathing system that saves Xenon.
 - Low breathing resistance so you can study sick patients.
 - Semi-automatic operation.
 - Remote Control Capability.
-

Get out of the FOG-making business, and call today for more information on putting gases where gases belong, with the XENAMATIC.

Also available, Model 2000.

For more information, please call or write,

Circle Reader Service No. 32



DIVERSIFIED DIAGNOSTIC PRODUCTS, INC.

11603 Windfern
Houston, TX 77064
713-955-5323



Become a member of the
**European Association
of Nuclear Medicine**

and receive the
European Journal of Nuclear Medicine

as part of your benefits and:


- Get to know Europe, our Hospitality and the Annual EANM Congress
- Attend our congresses at a significant discount
- Participate in our Committees and TaskGroup

All for: \$120

EANM Permanent Secretariat
Keizersgracht 782
NL-1017 EC Amsterdam The Netherlands
+31206269351
+31206259574 (F)



**The Finest Line of Cardiac
Gates Available**



Since 1979, AccuSync Medical Research Corporation has been serving the health care industry, offering the finest line of cardiac gates available on the market.

Our dedication to service combined with a commitment to provide you with a reliable product, have built the solid reputation of our gates.

With a complete line of models available, you are able to choose the gate with the features and capabilities that best correspond to your specific requirements.

The AccuSync 5L, our most full-featured model (featured at left) includes CRT monitor (visual) and Strip Chart Recorder (hard copy).

Model Specifications:

- Auto/Manual Trigger
- No delay
- ECG output
- Audio indicator
- Trigger pulse LED
- Isolation amplifier for patient safety
- Compatible with all computers

AccuSync 6L		AccuSync 1L		AccuSync 4M	
Model	Strip Chart	CRT Monitor	HR/R-R Int	Trigger	
5L	•	•	•	•	
6L		•	•	•	
1L	•		•	•	
4M				•	

Models 5L, 6L & 1L are CSA & ETL (UL544) Approved, Model 4M is CSA Approved


Accessories Available:

Patient cables, lead wires and BNC cables are available for all AccuSync models



132 Research Drive, Milford CT 06460
Phone (203) 877-1610 • Fax (203) 877-8972

Don't Practice Without It!



- Completely updated
- Fully referenced
- Authoritatively written
- Print and software
- 30 day MBG

To order or for more
information, call:
(303) 782-5208

Wick Publishing, Inc.
4720 East Oxford Avenue
Englewood, Co 80110 USA

Circle Reader Service No. 215

NOMINATIONS SOUGHT FOR

Benedict Cassen Prize

\$25,000 Award

To a scientist or physician-scientist
whose work has led to a major advance
in basic or clinical
nuclear medicine science.

Deadline: November 15, 1995

For more information, contact: Education & Research
Foundation, The Society of Nuclear Medicine, 1850
Samuel Morse Dr., Reston, VA 22090; or Sue Weiss,
C.N.M.T., Administrative Director (312) 880-4416.

SPECT BRAIN IMAGING CLINICAL FELLOWSHIP



Department of Radiology Section of Nuclear Medicine

BENEFIT

This program is designed for nuclear medicine physicians, radiologists, technologists and referring physicians. It is intended to educate participants about the clinical utility of SPECT brain imaging with agents such as Ceretec® and Neurolite®.

Objectives include:

- Development of interpretation skills for brain images.
- Appreciation of clinical applications of SPECT brain imaging.
- Knowledge of image acquisition and reconstruction.
- Appreciation of factors that influence image quality.
- Knowledge of quality control techniques for SPECT.

SPONSORSHIP:

This program is sponsored by the Medical College of Wisconsin.

TUITION:

The tuition fee of \$650 includes the course syllabus, handouts, breaks, breakfasts, lunches, and other amenities involved in making this a pleasant learning experience. Maximum enrollments have been established. Cancellations prior to the course will be refunded, less a \$30 administrative fee.

CREDIT:

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Accordingly, the Medical College of Wisconsin designates this continuing medical education activity as meeting the criteria for 13.00 hours in Category I toward the Physician's Recognition Award of the American Medical Association.

Nuclear Medicine Technologists who attend the SPECT Brain imaging Clinical Fellowship are eligible for 1.0 VOICE credit.

Register me for the following dates: (Please indicate a second choice)

- ☐ September 11-12, 1995 ☐ November 13-14, 1995

A check in the amount of \$650 should accompany this registration form and be made payable to the Medical College of Wisconsin. Telephone registrations must be confirmed by check within 10 days.

Name _____

Address _____

City/State/Zip _____

Office Phone _____

☐ **work address**

☐ **home address**

Registrations and payment should be sent to:

LisaAnn Trembath
SPECT Brain Imaging Fellowship Coordinator
Nuclear Medicine Division
Medical College of Wisconsin
8700 W. Wisconsin Avenue
Milwaukee, WI 53226
Phone: (414) 777-3756 • Fax: (414) 771-3460

Each description of the products below was condensed from information supplied by the manufacturer. The reviews are published as a service to the professionals working in the field of nuclear medicine and their inclusion herein does not in any way imply an endorsement by the Editorial Board of *The Journal of Nuclear Medicine* or by the Society of Nuclear Medicine.

The Label Printer That Goes Where You Go



Kroy Inc., has introduced a new method for printing labels and bar codes directly from your com-

puter's Windows™ based software. Windows and DOS® print capability is now available with its updated K2000 portable bar code and label printer. Users will be able to utilize programs like Microsoft® Word for Windows, Microsoft Excel and Strandware Quick Draw® for Windows to print durable labels that include TrueType™ fonts, bar codes, clip art and computer-scanned graphics. This improved portable printer allows users a wide range of versatility for every application. Weighing only 4.5 pounds, the K2000 is able to go anywhere you need bar code labels on demand. With 128K RAM, 256K ROM, eight bar code symbologies and six prompting languages built in, the K2000 can tackle the most demanding applications. Its RS-232 port can accept input from compatible scanners and sophisticated users can upload and download data to and from their computer. **Tricia Bosco, Kroy Inc., P.O. Box C-12279, Scottsdale, AZ 85267-2279.**

New Laser System From Polaroid

A chemically-free, totally digital imaging system for all radiology modalities has reached the medical market. The Helios 1417 Laser System from Polaroid provides sharp and clear images and makes it possible to eliminate silver-halide film and wet chemical processing, as well as the costs and hazards related to the use and disposal of toxic wastes from medical radiology. The new Helios system enables Polaroid to address all digital modalities, including CT, MRI and digital x-ray applications. The system consists of a carbon-based, digitally responsive film and a powerful laser imaging device that produces

diagnostic quality 14"×17" transparencies in seconds. Helios' laser technology creates high-resolution images on a unique carbon-based film that responds digitally to laser energy. The process, digital gray scaling, can produce more than 4000 shades of gray, resulting in superior sharpness, clarity and overall image quality. The Helios 1417 allows for more image information for diagnosis on each film with its 6-bit architecture capable of 12-bit printing. **Polaroid Medical Imaging Systems, 153 Needham Street, Building 3, Newton, MA 02164. Phone: (617) 386-4018.**

Open Platform=The New Image Management System

Built on open architecture, the 3M Image Management System is scalable and expandable to allow users to adopt the system as their needs grow. The new image management system offers application-designed, integrated solutions for remote viewing and filming, critical care area viewing, print redundancy and home or office viewing. Digital images can be captured from both DICOM and non-DICOM digital modalities, including computed radiographs, and routed anywhere on

the network. The viewing station is a high-resolution (2048 scan lines) workstation. Based on a Sun SPARC platform, the station offers the following functions: patient selection, modality-specific screen formatting and reformatting, image comparisons, annotation, next/previous image, 12-bit window/level, video invert, zoom up/down, pan, reset, film, transmit, help and system administration. **3M Health Care Customer Helpline (800) 228-3957, ext. 7-1332.**

New Venti-Scan III for Sharper DTPA Images



The new Venti-Scan III Radiaerosol System is a completely self-contained unit for the administration of technetium DTPA. Packaged individually, each disposal kit contains everything needed to perform a single study. The new nebulizer features a small baffle that produces a fine particle size to enhance delivery of the radioaerosol. The kit also includes the new HEPA filter, a pleated design that traps moisture, decreases breathing resistance and offers trapping efficiency. The unit also offers a new, completely enclosed shield design that provides lead-shielded protection from top to bottom. The shield slides along a standard intravenous pole to any comfortable patient height and locks into position. For ventilator-assisted patients, the top of the shield has a sliding port to accommodate the new Venti-Pack Accessory Kit. **Biomedex Medical Systems, Brookhaven R&D Plaza, P.O. Box 702, Shirley, NY 11967-0917. Phone: (800) 224-6339. Fax: (516) 924-9241.**

A Manageable Manual

PC Associates Ltd. introduces an easy to follow flow-chart manual for Sophy DSX-DS7 version 2.01 software. A reference tool for the novice or expert, this manual presents acquisition processing, patient database and system management guidelines. All general nuclear medicine procedures compiled in the manual are simplified in the acquisition and processing sections. Patient database and system management includes everything from camera quality control to efficient ways to handle patient files. Tested in a hospital setting, use of the manual has proven to be effective in streamlining any department, clinic or private office. **Scott Platsky, President, PC Associates Ltd., P.O. Box 84424, Phoenix, AZ 85071. Phone: (800) 347-1406.**

Classified Advertising

Positions Available

Nuclear Radiologist

NUCLEAR RADIOLOGIST BOARD CERTIFIED IN RADIOLOGY and BC/BE in Nuclear Medicine/Nuclear Radiology to share responsibilities in Diagnostic Radiology and Nuclear Medicine. We are a private teaching hospital practice with radiology residents covering two hospitals with 1,600 total beds. We perform 18,000 nuclear medicine procedures annually, with 30%-35% nuclear cardiology procedures. Modern equipment including dual-head SPECT cameras at both hospitals and a networked computer system. Staff includes 30 radiologists including 4 in nuclear medicine. Mail or fax CV inquiries to: M. Moinuddin, MD, Mid-South Imaging & Therapeutics, PA, 910 Madison, Suite 704, Memphis, TN 38103. Fax: 901-526-8707.

EXPERT CARE...



An Exceptional Spirit of Caring

Clarksville Memorial Hospital's status as a major health center for north Middle Tennessee and Southern Kentucky is confirmed by our commitment to the highest possible level of medical expertise and technology. The respected staff at our 216-bed facility also displays a special caring touch as they share the gift of health and improve the quality of life for all members of our regional community. Join our progressive hospital in the following career opportunity:

RADIATION PHYSICIST

This position in the modern, well-equipped Cancer Center includes responsibilities addressing diagnostic radiology, radiation therapy and nuclear medicine.

Our qualified candidate will have a minimum of five years experience in Radiological Physics, a Ph.D. or MS in Medical Physics, and certification in Radiological Physics by the American Board of Radiology and/or the American Board of Medical Physics.

The ability to speak and write clearly, and deal effectively with licensing agents is essential.


In addition to a competitive salary, we provide full benefits that include your choice of medical plans, as well as dental, vision, paid pension, tuition reimbursement and much more. To learn more, please fax or mail your resume to:

Debbi Coleman, Employment Manager, CLARKSVILLE MEMORIAL HOSPITAL, 1771 Madison St., Clarksville, TN 37043-3160. 615-551-1027 (FAX)


Clarksville Memorial
HOSPITAL
An Equal Opportunity Employer

Now Available

Bound Volumes of *The Journal of Nuclear Medicine*



The Society of Nuclear Medicine announces a new service to readers who need to make sure that every recent issue of JNM is right at hand.

Now you can order full sets of "library quality" bound volumes of *The Journal of Nuclear Medicine* for 1993 (Volume 34) and 1994 (Volume 35). The cost is \$195.00 including shipping and handling—little more than the same issues purchased separately as back copies.


Simply call Steve Klein at 703-708-9000, extension 213, to order.

Your new bound volumes—stamped with the Journal's name, volume, and date—will be delivered in six to eight weeks.

Elscint Advanced Digital Technology Expands Nuclear Imaging Horizons

Helix Simultaneous FDG/MIBI SPECT

MYOCARDIAL PERFUSION AND VIABILITY IN A SINGLE SCAN



A 51 year old female with unstable angina, hypertension and chronic obstruction pulmonary disease. Stress-rest Thallium scintigraphy revealed defects in the anterior wall and fixed defect in the inferolateral wall. PET imaging suggested hibernating myocardium in the inferior and inferolateral wall.

clinical image courtesy of **Vanderbilt University Medical Center, Nashville, TN**

Helix high-versatility digital camera design provides optimal imaging performance for every isotope and energy level, up to 511 keV. **Simultaneous dual-isotope SPECT acquisition of ^{18}F -FDG and $^{99\text{m}}\text{Tc}$ MIBI** potentially enhances the assessment of myocardial viability - at half the conventional scanning time.



Elscint *The Intelligent Image*

Helix The revolution never stops

Elscint/Belgium: (2) 720.92.46 Elscint/Brazil: (11) 869-4644 Elscint/Canada: (905) 474-1229 Elscint/U.S.A.: (201) 342-2020, 1-800 ELSCINT
Elscint/Central & Eastern Europe, Austria: (1) 9855-681 Elscint/France: (1) 48-57-08-18 Elscint/Germany: (61) 22-7070
Elscint/Hong-Kong: (5) 292231 Elscint/Israel: (9) 982-464 Elscint/Italy: (2) 39320603 Elscint/Mexico: (5) 254-5939
Elscint/South Africa: (11) 482-3000 Elscint/Spain: (3) 209.21.99 Elscint/UK: (923) 239511

Circle Reader Service No. 42



OptiCEL self-tuning digital detectors keep your nuclear systems out of the shop.

NEW OPTICEL™ DIGITAL DETECTORS. Sports cars aren't the only high-performance machines that need constant tuning. To get optimal image quality consistently, your digital gammacamera will need ongoing adjustment as well. The question is, "Will you have to sacrifice uptime to get it?" Not with OptiCEL digital detectors from Toshiba. OptiCEL digital detectors feature Optotune™, an exclusive self-tuning technology that automatically adjusts the digital detector. That means that your Toshiba gammacamera will stay up and running, not up on the rack.

Available on Toshiba's nuclear gammacamera systems, Optotune tunes the digital detector up to 512 times per second. That equates to super-crisp image quality every time, but of equal importance, it translates to exceptional reliability and maximum uptime. Digital detectors without Optotune may require service every two months to get similar tuning. And service time is downtime.



New OptiCEL digital detectors: powerful, self-tuned nuclear diagnostics designed to stay in service... and out of the shop. For more information call: 1-800-421-1968

In Touch with Tomorrow
TOSHIBA

GLOBAL IMAGING ■ MEDICAL SYSTEMS